FDA's Opioid REMS Proposal Has Narrow Focus On Education

Faced with data gaps, inadequate metrics and the need to maintain access to therapies, FDA takes a narrow approach to addressing long-acting and extended-release opioid abuse and misuse in its proposed Risk Evaluation and Mitigation Strategy for the painkillers